<DOC>
	<DOCNO>NCT01899859</DOCNO>
	<brief_summary>The primary objective study characterize safety , tolerability dose-limiting toxicity ( DLTs ) GR-MD-02 administer intravenously subject biopsy-proven NASH advance liver fibrosis .</brief_summary>
	<brief_title>Phase 1 Study Evaluate Safety GR-MD-02 Subjects With Non-Alcoholic Steatohepatitis ( NASH ) Advanced Fibrosis</brief_title>
	<detailed_description>This study dose range study assess sequential fashion , safety , tolerability , dose limit toxicity ( DLTs ) GR-MD-02 , subject biopsy-proven NASH advance fibrosis . This dose escalation design comprise 3 sequential cohort evaluate safety GR MD 02 administer single IV infusion follow 3 additional weekly infusion start 28 day first dose . Each cohort consist 8 subject , 6 randomize receive active drug 2 randomize receive placebo.Based data safety monitor board ( DSMB ) FDA review , 2 additional cohort may implement , consist 8 subject .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Subjects meet follow criterion consider admission study : 1 . Institutional Review Board ( IRB approve write Informed Consent privacy language per national regulation ( eg , Health Insurance Portability Accountability Act [ HIPAA ] Authorization US sit ) must obtain subject legally authorize representative prior study related procedure , include screen evaluation test . 2 . Subject â‰¥ 18 year age &lt; 75 year old time consent . 3 . Subject percutaneous liver biopsy within 12 month Screening show definitive diagnosis NASH advance ( Brunt stage 3 ) hepatic fibrosis . 4 . Sexually active male female childbearing potential must agree use adequate contraception ( condom , intrauterine contraceptive device , implant , injectables , sexual abstinence vasectomize partner ) throughout participation study 30 day last dose study drug . Women childbearing potential must negative urine pregnancy test within 7 day prior first dose . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Subjects meet follow criterion exclude study : 1 . Subject pregnant lactate female . 2 . Subject current , significant alcohol consumption history significant alcohol consumption period 3 consecutive month time within 1 year prior screen . Significant alcohol consumption define 20 gram per day females 30 gram per day male , average ( standard drink US consider 14 gram alcohol ) . 3 . Subject unable reliably quantify alcohol consumption base upon local study physician judgment . 4 . Subject use drug historically associate nonalcoholic fatty liver disease ( NAFLD ) ( amiodarone , methotrexate , systemic glucocorticoid , tetracycline , tamoxifen , estrogens dos great use hormone replacement , anabolic steroid , valproic acid , know hepatotoxin ) 2 week year prior Screening . 5 . Subject require use drug narrow therapeutic window metabolize CYP3A4 fast act opioids ( alfentanil fentanyl ) , immunosuppressive drug ( cyclosporine , sirolimus , tacrolimus ) , cardiovascular agent ( ergotamine , quinidine dihydroergotamine ) , select psychotropic agent ( pimozide ) . 6 . Subject prior plan ( study period ) bariatric surgery ( eg , gastroplasty , RouxenY gastric bypass ) . 7 . Subject concurrent infection include diagnosis fever unknown origin evidence possible central line sepsis ( subject must afebrile start therapy ) . 8 . Subject platelet count 100,000/mm3 Screening . 9 . Subject clinical evidence hepatic decompensation define presence follow abnormality Screening : 1 . Serum albumin less 3.5 grams/deciliter ( g/dL ) . 2 . An INR great 1.1 . 3 . Direct bilirubin great 1.3 milligram per deciliter ( mg/dL ) . 10 . Subject history bleed esophageal varix , ascites hepatic encephalopathy 11 . Subject history hepatitis C. Patients find screen hepatitis C antibody , even PCR negative HCV RNA , exclude study . 12 . Subject evidence form chronic liver disease : 1 . Hepatitis B define presence hepatitis B surface antigen . 2 . Evidence ongoing autoimmune liver disease define compatible liver histology . 3 . Primary biliary cirrhosis define presence least 2 criterion ( ) Biochemical evidence cholestasis base mainly alkaline phosphatase elevation ( ii ) Presence antimitochondrial antibody ( iii ) Histologic evidence nonsuppurative destructive cholangitis destruction interlobular bile duct . 4 . Primary sclerosing cholangitis . 5 . Wilson 's disease define ceruloplasmin limit normal compatible liver histology . 6 . Alpha1antitrypsin deficiency define diagnostic feature liver histology ( confirm alpha1 antitrypsin level less normal ; exclusion discretion study physician ) . 7 . History hemochromatosis iron overload define presence 3+ 4+ stainable iron liver biopsy . 8 . Druginduced liver disease define basis typical exposure history . 9 . Known bile duct obstruction . 10 . Suspected proven liver cancer . 11 . Any type liver disease NASH . 13 . Subject serum ALT great 300 unit per liter ( U/L ) Screening . 14 . Subject serum creatinine 1.5 mg/dL great Screening . 15 . Subject use prescription overthecounter medication herbal remedy believe improve treat NASH liver disease obesity period begin 30 day prior randomization . Subjects use Vitamin E omega3 fatty acid may continue use . 16 . Subject major surgery within 8 week prior Day 0 , significant traumatic injury , anticipation need major surgical procedure course study . 17 . Subject history biliary diversion . 18 . Subject know positivity Human Immunodeficiency Virus infection . 19 . Subject active , serious medical disease likely life expectancy le 5 year . 20 . Subject active substance abuse , include inhale injection drug , year prior Screening . 21 . Subject clinically significant uncontrolled cardiovascular disease ( eg , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 12 month prior Day 0 . 22 . Subject participate investigational new drug ( IND ) trial 30 day randomization . 23 . Subject clinically significant medical psychiatric condition consider high risk participation investigational study . 24 . Subject condition , opinion Investigator , would impede compliance hinder completion study . 25 . Subject previously expose GR MD 02 . 26 . Subject know allergy study drug excipients . 27 . Subject malignant disease ( basal squamous cell carcinoma skin situ carcinoma cervix ) least 5 year followup show recurrence . 28 . Subject abnormal chest xray indicative acute chronic lung disease screen examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Non-Alcoholic Steatohepatitis ( NASH )</keyword>
</DOC>